Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bilous

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 20, 2003
Current perspectives on HER2 testing: a review of national testing guidelinesMichael Bilous, Mitch Dowsett, Wedad Hanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patientsAlexandra F Leary, Wedad M Hanna, Marc J van de Vijver, et al.
Journal of Clinical Pathology|January 10, 2014
The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancerNirmala Pathmanathan, Rosemary L Balleine, Upali W Jayasinghe, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 29, 2013
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityWedad M Hanna, Josef Rüschoff, Michael Bilous, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|November 6, 2010
Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practiceGelareh Farshid, Jane E Armes, Richard Bell, et al.
Genes, Chromosomes & Cancer|September 4, 2010
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case familiesRosemary L Balleine, Pamela J Provan, Gulietta M Pupo, et al.
The American Journal of Surgical Pathology|February 9, 2012
Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in AustraliaStephen B Fox, Marian Priyanthi Kumarasinghe, Jane E Armes, et al.
Asia-Pacific Journal of Clinical Oncology|September 18, 2014
Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task forceKyoung-Mee Kim, Michael Bilous, Kent-Man Chu, et al.
Breast Cancer Research and Treatment|June 9, 2012
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization ProgramMichael Bilous, Adrienne L Morey, Jane E Armes, et al.
Archives of Pathology & Laboratory Medicine|May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAntonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 20, 2003
Current perspectives on HER2 testing: a review of national testing guidelinesMichael Bilous, Mitch Dowsett, Wedad Hanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patientsAlexandra F Leary, Wedad M Hanna, Marc J van de Vijver, et al.
Journal of Clinical Pathology|January 10, 2014
The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancerNirmala Pathmanathan, Rosemary L Balleine, Upali W Jayasinghe, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 29, 2013
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityWedad M Hanna, Josef Rüschoff, Michael Bilous, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|November 6, 2010
Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practiceGelareh Farshid, Jane E Armes, Richard Bell, et al.
Genes, Chromosomes & Cancer|September 4, 2010
Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case familiesRosemary L Balleine, Pamela J Provan, Gulietta M Pupo, et al.
The American Journal of Surgical Pathology|February 9, 2012
Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in AustraliaStephen B Fox, Marian Priyanthi Kumarasinghe, Jane E Armes, et al.
Asia-Pacific Journal of Clinical Oncology|September 18, 2014
Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task forceKyoung-Mee Kim, Michael Bilous, Kent-Man Chu, et al.
Breast Cancer Research and Treatment|June 9, 2012
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization ProgramMichael Bilous, Adrienne L Morey, Jane E Armes, et al.
Archives of Pathology & Laboratory Medicine|May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateAntonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
Pageof 5